...
首页> 外文期刊>Frontiers in Cell and Developmental Biology >The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs
【24h】

The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs

机译:C-X-C主题趋化因子配体1维持乳腺癌干细胞自我更新,促进肿瘤进展和免疫逃生计划

获取原文
           

摘要

Breast cancer (BC) mortality is mainly due to metastatic disease, which is primarily driven by cancer stem cells (CSC). The chemokine C-X-C motif ligand-1 (CXCL1) is involved in BC metastasis, but the question of whether it regulates breast cancer stem cell (BCSC) behavior is yet to be explored. Here, we demonstrate that BCSCs express CXCR2 and produce CXCL1, which stimulates their proliferation and self-renewal, and that CXCL1 blockade inhibits both BCSC proliferation and mammosphere formation efficiency. CXCL1 amplifies its own production and remarkably induces both tumor-promoting and immunosuppressive factors, including SPP1/OPN, ACKR3/CXCR7, TLR4, TNFSF10/TRAIL and CCL18 and, to a lesser extent, immunostimulatory cytokines, including IL15, while it downregulates CCL2, CCL28 and CXCR4. CXCL1 downregulates TWIST2 and SNAI2, while boosts TWIST1 expression in association with the loss of E-Cadherin, ultimately promoting BCSC epithelial-mesenchymal transition. Bioinformatic analyses of transcriptional data obtained from BC samples of 1084 patients, reveals that CXCL1 expressing BCs mostly belong to the Triple-Negative subtype, and that BC expression of CXCL1 strongly correlates with that of pro-angiogenic and cancer promoting genes, such as CXCL2-3-5-6, FGFBP1, BCL11A, PI3, B3GNT5, BBOX1 and PTX3, suggesting that the CXCL1 signaling cascade is part of a broader tumor-promoting signaling network. Our findings reveal that CXCL1 functions as an autocrine growth factor for BCSCs and elicits primarily tumor progression and immune escape programs. Targeting the CXCL1/CXCR2 axis could restrain the BCSC compartment and improve the treatment of aggressive BC.
机译:乳腺癌(BC)死亡率主要是由于转移性疾病,主要由癌症干细胞(CSC)驱动。趋化因子C-X-C motif配体-1(CXCL1)参与了BC转移,但尚未探索其调节乳腺癌干细胞(BCSC)行为的问题。在这里,我们证明BCSCS表达CXCR2并产生CXCL1,其刺激其增殖和自我更新,并且CXCL1阻断抑制BCSC增殖和乳腺层形成效率。 CXCL1放大其自身的生产,显着诱导肿瘤促进和免疫抑制因子,包括SPP1 / OPN,AckR3 / CXCR7,TLR4,TNFSF10 / TRAP和CCL18,以及在较小程度上,免疫刺激细胞因子,包括IL15,而其下调CCL2, CCL28和CXCR4。 CXCL1下调Twist2和Snai2,同时提高Twist1表达与E-Cadherin的丧失结合,最终促进BCSC上皮 - 间充质转换。从1084名患者的BC样品获得的转录数据的生物信息分析表明,表达BCS的CXCL1主要属于三阴性亚型,并且CXCL1的BC表达与促血管生成和癌症促进基因的BC表达强烈相关,例如CXCL2- 3-5-6,FGFBP1,BCL11A,PI3,B3GNT5,BBOX1和PTX3,表明CXCL1信令级联是更广泛的肿瘤促进信令网络的一部分。我们的研究结果表明,CXCL1作为BCSCs的自分泌生长因子,主要是肿瘤进展和免疫逃生计划。靶向CXCL1 / CXCR2轴可以抑制BCSC隔间并改善侵略性BC的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号